MYCOLab Ai Logo - gold and army green

Research Progress of Cordyceps Sinensis and its Fermented Mycelium Products on Ameliorating Renal Fibrosis by Reducing Epithelial-to-Mesenchymal Transition

Summary

This research examines how Cordyceps sinensis, a traditional Chinese medicinal mushroom, and products made from it can help treat kidney disease by reducing scarring in kidney tissue. The study shows these treatments work by controlling inflammation and preventing certain harmful cellular changes. Impacts on everyday life: – Provides new treatment options for chronic kidney disease patients – Demonstrates the potential of traditional medicines when scientifically validated – Offers safer alternatives with fewer side effects than some conventional treatments – Shows promise for combining traditional and modern medicines effectively – Could help reduce healthcare costs through prevention of kidney disease progression

Background

Renal fibrosis is a hallmark and common outcome of various chronic kidney diseases (CKD), manifesting as excessive accumulation and deposition of extracellular matrix (ECM) in the kidney. The process involves inflammatory cell infiltration, myofibroblast activation, ECM production, tubular atrophy and microvascular rarefaction. Epithelial-to-mesenchymal transition (EMT) has been shown to be an important mechanism in renal fibrosis development.

Objective

To comprehensively review and evaluate the effectiveness of Cordyceps sinensis and its fermented mycelium products in alleviating renal fibrosis through antagonizing EMT, including their pharmacologic actions, mechanisms, and clinical applications.

Results

C. sinensis demonstrated anti-fibrotic effects across various animal models primarily through TGF-β1 dependent signaling pathways. It inhibited EMT and reduced ECM deposition through multiple mechanisms including MAPK signaling, SIRT1 signaling, and NF-κB signaling. Clinical studies showed improved renal function when C. sinensis products were combined with conventional treatments, though more rigorous trials are needed.

Conclusion

C. sinensis and its fermented mycelium products show promise in ameliorating renal fibrosis by inhibiting EMT and reducing ECM via multiple signaling pathways. The main mechanisms involve inhibition of TGF-β1 production and anti-inflammatory effects. While clinical data supports their therapeutic role, more research including renal biopsy data is needed to fully validate their anti-fibrotic effects.
  • Published in:Journal of Inflammation Research,
  • Study Type:Review,
  • Source: 10.2147/JIR.S413374
Scroll to Top